Lupin gets USFDA nod to market anti-fungal capsules
Lupin has got a nod from US health regulator USFDA to market its Flucytosine capsules used for treatment of fungal infections
New Delhi: Drug firm Lupin has received nod from the US health regulator to market its Flucytosine capsules used for treatment of fungal infections.
The company has received final approval to market its Flucytosine capsules USP, in the strengths of 250 mg and 500 mg, from the United States Food and Drug Administration (USFDA), Lupin said in a statement.
The product is generic version of Valeant Pharmaceuticals International Inc’s Ancobon capsules in the same strengths, it added.
The capsules are indicated for the treatment of serious infections caused by susceptible strains of Candida and/or Cryptococcus, Lupin said.
As per IMS MAT March 2017 data, Ancobon capsules had US sales of $46.6 million, it added.
The company’s cumulative filings with the USFDA now stand at 368. It has received approvals for 218 products while 150 product filings are pending approval.
Shares of Lupin Ltd were on Monday trading at Rs1,152.75 per scrip in the afternoon trade on BSE, up 3.22% from its previous close.
- BSNL aims to sell 10,000 satellite phones by March 2019
- Infosys says increased visa application rejections could result in delays, higher project costs
- Change M&A norms to calculate spectrum dues: Trai
- Cracking India’s bankruptcy code
- RBI’s registry will help solve problem of credit shortage: iSpirt’s Sharad Sharma
Editor's Picks »
- Chief technology officers of Reliance Jio, Bharti Airtel quit
- IIT-Bombay generates ₹17.99 crore revenue in 2017-18, highest among IITs
- EPFO payroll data shows 4.4 million jobs created in 9 months till May
- Dubai recipe for economic success looks stale as markets slump
- CWC meet: Rahul Gandhi says BJP attacks institutions, Dalits, and poor
- What ABB India’s performance in June quarter says about capex growth
- Bajaj Finance does well in Q1 even as competition hots up
- Kotak Mahindra Bank: The perils of being priced to perfection
- Higher cane price crushes hopes of sugar mills
- Market optimism before 2019 general election: History may not repeat itself